Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

Pharmacogenetics and Genomics

Volumn 26, Issue 2, 2016, Pages 80-87

  Lv, Jinfeng ^a   Hu, Lei ^a   Zhuo, Wei ^a   Zhang, Congmin ^a   Zhou, Honghao ^a   Fan, Lan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bupropion; CYP2B6; Genetic polymorphism; Hydroxybupropion; P450 oxidoreductase

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; RADAFAXINE; CYTOCHROME P450;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOCHROME P450 OXIDOREDUCTASE GENE; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; ENZYME ACTIVITY; GENE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC POLYMORPHISM; GENETICS; HYDROXYLATION; METABOLISM;

BUPROPION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; POLYMORPHISM, GENETIC;

EID: 84983097844     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000190     Document Type: Article

References (48)

1. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 2007; 62:635-641.
2. Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion's smoking-cessation pharmacology: The role of hydroxybupropion. Clin Pharmacol Ther 2012; 92:771-777.
3. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics 2013; 23:135.
4. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28:1222-1230.
5. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 2009; 65:403-409.
6. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003; 13:619-626.
7. Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos 2014; 42:1971-1977.
8. Wang HB, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008; 9:598-610.
9. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenet Genomics 2001; 11:399-415.
10. Jacob RM, Johnstone EC, Neville MJ, Walton RT. Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin Chem 2004; 50:1372-1377.
11. Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K, et al. A natural CYP2B6 TATA box polymorphism (- 82T→C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 2005; 67:1772-1782.
12. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-873.
13. Guan S, Huang M, Chan E, Chen X, Duan W, Zhou SF. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci 2006; 29:14-21.
14. Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, Shin SG, et al. Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos 2004; 32:1341-1344.
15. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, et al. Homozygous CYP2B6 ∗6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenzcontaining regimens. Biochem Biophys Res Commun 2004; 319:1322-1326.
16. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006; 80:75-84.
17. Gao L, He Y, Tang J, Yin J, Huang Z, Liu F, et al. Genetic variants of pregnane X receptor (PXR) and CYP2B6 affect the induction of bupropion hydroxylation by sodium ferulate. Plos One 2013; 8:e62489.
18. Gigon PL, Gram TE, Gillette JR. Studies on the rate of reduction of hepatic microsomal cytochrome P-450 by reduced nicotinamide adenine dinucleotide phosphate: Effect of drug substrates. Mol Pharmacol 1969; 5:109-122.
19. Ullrich V. On the hydroxylation of cyclohexane in rat liver microsomes. Hoppe Seylers Z Physiol Chem 1969; 350:357-365.
20. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003; 278:25895-25901.
21. Xue X, Gong L, Qi X, Wu Y, Xing G, Yao J, et al. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Toxicol Lett 2011; 205:47-54.
22. Hu L, Zhuo W, He YJ, Zhou HH, Fan L. Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenet Genomics 2012; 22:812-819.
23. Miller WL, Huang N, Agrawal V, Giacomini KM. Genetic variation in human P450 oxidoreductase. Mol Cell Endocrinol 2009; 300:180-184.
24. Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima-Uesaka H, Sugimoto D, et al. Genetic polymorphisms and haplotypes of POR encoding cytochrome P450 oxidoreductase in a Japanese population. Drug Metab Pharmacokinet 2011; 26:107-116.
25. Arlt W. P450 oxidoreductase deficiency and Antley-Bixler syndrome. Rev Endocr Metab Disord 2007; 8:301-307.
26. Scott RR, Miller WL. Genetic and clinical features of P450 oxidoreductase deficiency. Horm Res 2008; 69:266-275.
27. Miller WL. P450 oxidoreductase deficiency: A new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 2004; 15:311-315.
28. Pandey AV, Sproll P. Pharmacogenomics of human P450 oxidoreductase. Front Pharmacol 2014; 5:103.
29. Chen X, Pan LQ, Naranmandura H, Zeng S, Chen SQ. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PloS One 2012; 7:e38495.
30. Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab Dispos 2012; 40:754-760.
31. Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 2010; 20:611-618.
32. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase∗ 28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011; 12:1281-1291.
33. Yang G, Fu Z, Chen X, Yuan H, Yang H, Huang Y, et al. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: A randomized, open-label, crossover study in healthy Chinese men. Clin Ther 2011; 33:2060-2070.
34. Zhang X, Li L, Ding X, Kaminsky LS. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 2011; 39:1433-1439.
35. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 2009; 19:877-883.
36. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 2010; 20:677-686.
37. Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 2014; 70:685-693.
38. Gijsen VM, van Schaik RH, Soldin OP, Soldin SJ, Nulman I, Koren G, et al. P450 oxidoreductase∗ 28 (POR∗ 28) and tacrolimus disposition in pediatric kidney transplant recipients - A pilot study. Ther Drug Monit 2014; 36:152-158.
39. Elens L, Nieuweboer AJ, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, et al. Impact of POR∗ 28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics 2013; 23:148-155.
40. Drogari E, Ragia G, Mollaki V, Elens L, Van Schaik RH, Manolopoulos VG. POR∗ 28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics 2014; 15:1963-1972.
41. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199:193-209.
42. Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 2010; 20:520.
43. Tan SL, Li Z, Zhang W, Song GB, Liu LM, Peng J, et al. Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. Eur J Clin Pharmacol 2013; 69:1769-1775.
44. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008; 105:1733-1738.
45. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009; 10:579-599.
46. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59:366-373.
47. Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh- Geiss J. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3:131-140.
48. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004; 66:675-682.